Matrin CYP, an SR-rich Cyclophilin That Associates with the Nuclear Matrix and Splicing Factors*

Michael J. Mortillaro and Ronald BerezneyDagger

From the Department of Biological Sciences, State University of New York, Buffalo, New York 14260

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We report the identification and cloning of a nuclear matrix protein termed matrin cyclophilin or matrin CYP. The derived sequence of matrin cyp encodes a protein of 752 amino acids with a predicted mass of 88 kDa. A 172-residue stretch at the amino terminus shows high identity with the ubiquitous family of cyclophilins. Clustered throughout the carboxyl half of the protein are a series of serine-arginine (SR) repeats that are a characteristic feature of many RNA splicing factors. Antibodies raised against matrin CYP recognize a 106-kDa antigen that is detected in isolated nuclei and quantitatively subfractionates in the nuclear matrix. Laser scanning confocal microscopy localizes most of the anti-matrin CYP-specific antigen within the nucleus in a pattern of large bright speckles that co-localize with splicing factors and diffuse nucleoplasmic staining. A strikingly similar pattern of staining is observed in cells extracted for in situ nuclear matrices. A fusion protein containing the cyclophilin domain of matrin CYP exhibits cyclosporin A (CsA)-sensitive, peptidylprolyl cis-trans-isomerase activity that is characteristic of native cyclophilins. Although total rat liver nuclei contains predominantly CsA-resistant PPIase activity, the corresponding activity in the nuclear matrix is largely CsA-sensitive.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The many functions associated with the cell nucleus are temporally and spatially regulated. Nuclear proteins and nucleic acids are often partitioned into functional domains (1). Examples include the nucleoli, heterochromatin, DNA replication sites (2, 3), and transcription domains (4, 5). In addition, a number of other domains have been identified that may also perform specific functions, such as the nuclear speckles (1, 6) and coiled (7) and promyelocytic leukemia (8-10) bodies. Determining which molecules comprise these structures and how these molecules interact will lead to a greater understanding of the mechanisms responsible for their diverse functions and the role of nuclear architecture in these processes.

The proteins and nucleic acids in the cell nucleus that resist solubilization by high salt extraction, nuclease digestion, and detergent solubilization constitute a structure termed the nuclear matrix (11, 12). The isolated nuclear matrix has been shown to maintain a structure similar to and containing many of the functional properties associated with the nucleus (13). Several major proteins of the internal nuclear matrix have been identified by immunological methods and termed the nuclear matrins (14). The nuclear matrins include previously characterized proteins such as human RNP1 A, human nRNP B (15), the nucleolar protein, B23/numatrin (14, 16), the hyperphosphorylated form of RNA pol II LS (17, 18), numerous SR-related proteins (19), and a 125-kDa acidic protein, termed matrin 3 (20). A recent study has confirmed the RNP nature of many of the major nuclear matrix proteins (21).

Here we present results on the isolation of a cDNA that encodes an 88-kDa protein with a cyclophilin domain at the amino terminus and a series of SR repeats throughout the carboxyl half of the protein. This protein, termed matrin cyclophilin or matrin CYP, is enriched in the nuclear matrix, co-localizes with splicing factors at nuclear speckles, and undergoes dynamic rearrangement during mitosis. Matrin CYP fusion protein expresses a cyclosporin A (CsA)-sensitive peptidylprolyl cis-trans-isomerase (PPIase) activity that is characteristic of cyclophilins. We further measure, for the first time, PPIase activity in isolated cell nuclei and demonstrate the quantitative recovery of total nuclear CsA-sensitive activity in the nuclear matrix.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Screening of a Rat Insuloma Library-- A random primer digoxigenin-11 dUTP-labeled rat liver partial length cDNA probe was used to screen a pCD-X rat insuloma library (22) via colony hybridization. The probe was detected with the Genius chemiluminescence kit (Boehringer Mannheim). 250,000 colonies were screened and two positives obtained from the quaternary screening. Both positives contained similar sized inserts, and their restriction maps were indistinguishable.

Sequence Analysis of Matrin cyp cDNA-- Twelve fragments encompassing the entire matrin CYP full-length cDNA were subcloned into pGEM-3Z (Promega) and sequenced. Sequencing was performed by the dideoxy method using [35S]dATP and the Sequenase 2.0 kit (U. S. Biochemical Corp.) (23). Additional sequencing was performed over ambiguous regions using synthesized oligo primers (Integrated DNA Technologies). Each fragment was sequenced in the forward and reverse directions, and overlapping sequence was obtained for parts of the cDNA. The cDNA sequence was assembled and analyzed using the GCG computer package. The EMBL, Swiss-protein, and National Institutes of Health nucleotide and amino acid data bases were searched for homology to the matrin cyp cDNA using FASTA, BLAST, and BLITZ programs.

Construction, Expression, and Purification of GST/Matrin CYP-CT and GST/Matrin CYP: NT Fusion Proteins-- For GST/matrin CYP-CT a 389-bp region from the matrin CYP cDNA corresponding to nucleotides 1930-2319 was amplified (GeneAmp, Perkin-Elmer) using the following primers with engineered restriction sites: 5'-GATGGATCCAGCCAAGACAGTAAGAGTTCACACAG and 3'-GCAGAATTCGAGGGAGGCTCTTGAAAAGTAGAC (Integrated DNA Technologies). A 536-bp region from the matrin cyp cDNA corresponding to nucleotides 1-536 was amplified using the following primers: 5'-CAATCGGATCCATGGGAATAAAGGTTCAGCGTCC and 3'-GACGAATTCAACCAGCTCTCCACAACTGAGTATC for GST/matrin CYP-NT. These amplified fragments were digested with EcoRI and BamHI and subcloned into pGEX-kt (24). The open reading frame and sequence of the pGEX-kt subclones were verified by DNA sequencing. Each plasmid was transformed into JM101 and a single recombinant colony transferred to 1 liter of LB media. The fusion protein was purified by a previously described procedure (25) except that the cells were induced with 0.1 mM isopropyl beta -D-thiogalactopyranoside, lysed in a French press (p.s.i. = 18,000), and the fusion proteins were purified over a 1-ml glutathione-agarose bead column (Sigma). The GST/matrin CYP-CT fusion protein was cleaved with thrombin (Sigma) while still associated with the column and the eluate recovered as matrin CYP-CT. Conversely, the GST/matrin CYP-NT was not cleaved with thrombin but eluted intact from the glutathione-agarose bead column. The GST/NK-TR (26) and GST alone were expressed and purified identically to GST/matrin CYP-NT. The various fusion protein fractions were run on a 10% SDS-polyacrylamide gel using standard procedures and stained with Coomassie Blue or processed for immunoblot analysis (described below). The fusion proteins were quantified using the BCA protein detection kit (Pierce).

Preparation and Purification of Polyclonal Antibodies against Matrin CYP-CT-- 1 mg of the protein was emulsified in 300 µl of Freund's complete adjuvant and then injected intramuscularly into a 28-week-old leghorn hen. After 3 weeks a boost of 500 µg of matrin CYP-CT in incomplete Freund's adjuvant was given, and the eggs produced by this chicken were immediately retrieved. A total of three booster shots were separated by 4-week intervals. Isolation of IgY from egg yolks was performed as described previously (27). Antibodies were further purified by passage over a 1-ml affinity column of matrin CYP-CT linked to Sepharose 4B (Amersham Pharmacia Biotech). The antibody preparation showed no detectable cross-reactivity with the GST portion of the fusion protein.

Subcellular Fractionation and Nuclear Matrix Isolation from Rat Liver Cells-- Livers were extracted from adult male Sprague-Dawley rats and processed for rat liver matrices using exogenously added DNase I (28). The supernatants of the washes from the extraction procedures were saved for later use. Additionally, the first post-nuclear supernatant was retained for separation into various cytoplasmic subfractions. A 10,000 × g·h centrifugation separated a crude mitochondrial pellet and post-mitochondrial supernatant. Next, centifugation of the post-mitochondrial supernatant at 100,000 × g·h resulted in a microsomal pellet and cytosol supernatant. Protein fractions were quantified by the BCA protein detection kit (Pierce) and separated by 7.5% SDS-polyacrylamide gel electrophoresis.

Phosphatase Treatment-- Rat liver nuclear matrices were pelleted to the bottom of a microcentrifuge tube and treated with potato acid phosphatase (Sigma) at a concentration of 0.4 units of phosphatase per µg of nuclear matrix protein for 14 h at 20 °C (29). Samples were resolved on a 7.5% SDS-polyacrylamide gel and immunoblotted as described below.

Immunoblot Analysis-- Protein samples run on an SDS-polyacrylamide gel were transferred overnight by wet transfer to a nitrocellulose filter (Schleicher & Schuell). The filter was incubated for at least 3 h in blocking buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Tween 20, 6% nonfat dry milk) at room temperature. The filter was incubated for 2 h with anti-matrin CYP-CT (1:500 dilution) in blocking buffer. The filter was washed 3 times with blocking buffer (minus the nonfat dry milk) for 5 min per wash. Goat anti-chicken IgG linked to alkaline phosphatase (1:5000 dilution) (Kirkegaard & Perry Laboratories) was incubated with the filter for 1 h at room temperature. The blot was washed four times as above and developed in 1 M Tris (pH 9.5), 10 mg/ml nitro blue tetrazolium, and 100 mg/ml bromochloroindolyl phosphate. Some bands were quantified by scanning densitometry.

Indirect Immunofluorescence Confocal Microscopy-- Rat parenchymal cells were prepared from rat liver tissue (30). These cells were grown on coverslips in Dulbecco's modified Eagle's medium and 10% fetal calf serum for 1 or 2 days. Mouse 3T3 fibroblasts were grown on coverslips as described previously (3). For mitotic studies, cells were first collected into G0 by incubating in 0.5% calf serum and Dulbecco's modified Eagle's medium for 3 days and released from the G0/G1 block by the addition of 10% calf serum in Dulbecco's modified Eagle's medium. After 22 h the maximum number of cells were in mitosis and used for analysis. For immunofluorescence, cells were washed quickly in three changes of PBS and typically fixed with 3% paraformaldehyde for 4 min on ice. Other fixation conditions included 3% paraformaldehyde for 10 min at 20 °C, 100% methanol for 2 min at -20 °C (31), acetone/ethanol (1:1) for 1 min at -20 °C (32), or treatment with CSK buffer followed by paraformaldehyde (33). Fixed cells were incubated with blocking buffer (10% goat serum, 0.5% Tween 20, and 3 mM MgCl2) in PBS for 30 min followed by reaction with anti-matrin CYP-CT (1:20 dilution) in the above blocking buffer at 37 °C for 1 h. Following three washes with 0.5% Tween 20 in PBS, the cells were incubated in goat anti-chicken IgG-fluorescein isothiocyanate (Kirkegaard & Perry Laboratories) at 37 °C for 30 min, washed 3 times with 0.5% Tween 20 in PBS, incubated with the second primary antibody, and washed as above. The red signal was enhanced by incubation with a biotinylated secondary antibody and streptavidin conjugated to Texas Red (Life Technologies, Inc.). Finally, the coverslips were washed 4 times in PBS and then mounted in SlowFade (Molecular Probes). Cells were observed by epifluorescence and laser scanning confocal microscopy with an Olympus GB200 laser scanning confocal microscope equipped with a 25-milliwatt argon laser operating at 488 and 514 nm. Images were corrected for inter-channel leakage using a leakage factor computed from a calibration image. The calibration image was obtained from a sample that is single labeled with fluorescein isothiocyanate-conjugated antibodies, and information was acquired on both channels. In situ nuclear matrices were prepared from rat parenchymal cells as previously reported (20).

Peptidylprolyl cis-trans-Isomerase (PPIase) Assay-- PPIase activity was determined as described previously (26, 34). Briefly, the cis-proline containing tetrapeptide substrate, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma), was converted to the trans-proline isomer and made accessible to protease cleavage by chymotrypsin resulting in an increase in absorbance of the product at 405 nm. Approximately 65% or 65 µM substrate was in the cis-isomer at the start of the assay measurements. Absorbance readings were collected every second using the double beam Hitachi U2000 spectrophotometer. To simplify analysis, the assay was performed under conditions in which [s] <<  Km. These reaction conditions enabled calculation of the first-order kinetic rate constant (kcat/Km) using the PSI-Plot program. The IC50 of CsA was determined with 100 nM GST/matrin CYP-NT and 65 µM cis-substrate as described (26).

Measuring PPIase Activity in Isolated Rat Liver Nuclear and Nuclear Matrix Proteins-- Nuclei and nuclear matrices were concentrated by centrifugation for 5000 × g·h at 4 °C. The pellets were solubilized in 9 M urea, 50 mM DTT, 2 M NaCl, 5 mM EDTA, and 20 mM Tris (pH 7.4) for 10 min on ice with mixing and then centrifuged for 5000 × g·h to remove insoluble material. The solubilized total nuclear or nuclear matrix proteins were dialyzed 2 times against 100 volumes of 200 mM NaCl and 20 mM Tris (pH 7.4) at 4 °C for 8 h and used in the PPIase assays following centrifugation for 5000 × g·h. All buffers contained the protease inhibitors 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml N-tosyl-L-phenylalanine chloromethyl ketone, 1 µg/ml leupeptin, and 1 µg/ml pepstatin A. Typically 25 µg of solubilized rat liver nuclear or nuclear matrix proteins were incubated with the cis-proline containing substrate, N-succinyl-AAPF-p-nitroanilide, and the activities of total proline isomerization was measured in micromoles of cis-substrate converted to trans-substrate (34). Incubating solubilized fractions with 10 µM CsA allowed determination of cyclophilin-catalyzed PPIase activity. Thermal nonenzymatic proline isomerization values were subtracted from observed protein induced activities to obtain actual values of PPIase activity. For each sample n = 2 or 3.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Molecular Cloning and Sequence Analysis of the Matrin CYP cDNA-- Chicken polyclonal antibodies raised against a nuclear matrix protein of approximately 106 kDa were used to isolate a rat liver cDNA from a lambda gt11 expression library. The expressed fusion protein from this clone reacted with the antisera, and when sequenced appeared to constitute only the 3' portion of a full-length transcript (data not shown).

By using the partial length cDNA as a probe, a 3971-bp full-length cDNA was isolated from a rat insuloma cDNA library. Sequencing of this cDNA, referred to as matrin CYP, revealed that it contains the partial length cDNA sequence as well as a continuous open reading frame of 2256 bp (Fig. 1B). The ATG at position +1 is a likely candidate for the start codon since the nucleotides around this ATG show near identity to the "Kozak" ribosome binding consensus sequence, and five codons upstream of this ATG is a termination codon (35). The 3'-untranslated region contains two consensus polyadenylation signals (e.g. AAUAAA). The consensus polyadenylation signal located at nucleotide 3557 appears to be utilized by the full-length rat insuloma cDNA.


View larger version (75K):
[in this window]
[in a new window]
 
Fig. 1.   The nucleotide and derived amino acid sequence of matrin CYP. A, a schematic representation of the derived amino acid sequence of matrin CYP indicating the cyclophilin domain (open box), the acidic serine domain (solid box), and the SR repeat regions (stippled boxes). The predicted molecular mass of matrin CYP is 88 kDa, and the predicted isoelectric point is 11.05. The boxes labeled GST/matrin CYP-NT and GST/matrin CYP-CT represent the regions corresponding to the amino-terminal and carboxyl-terminal fusion protein, respectively. B, the nucleotide sequence of the full-length matrin cyp cDNA with the predicted amino acid sequence below. The putative polyadenylation signals are single underlined in the 3'-untranslated region. The cyclophilin domain is single underlined, the acidic serine region is dashed underlined, and the SR repeats are double underlined.

The open reading frame of matrin cyp encodes a polypeptide of 752 amino acids. The derived amino acid sequence has a predicted molecular mass of 88,072 daltons and an isoelectric point of 11.05. One intriguing aspect of this amino acid sequence is the preponderance of charged and serine residues as follows: arginine and lysine residues account for 29%, aspartate and glutamate for 16%, and serines for 15% of the total number of residues of matrin CYP (Fig. 1B). Southern and Northern blot analyses indicates that matrin CYP in rat liver is coded for by one gene and contains one transcript whose size is consistent with the cloned cDNA fragments (data not shown).

Searching computer data bases for similarities to the nucleotide and predicted amino acid sequences identified two regions within the amino acid sequence that show striking similarity to several previously cloned and characterized proteins (Fig. 1A). The first of these domains is located between residues 6 and 178 (Fig. 1B). This region shows a high level of identity with several distinct cyclophilin proteins. Cyclophilin domains have been demonstrated to function as both a proline isomerase and a molecular chaperone (36, 37).

The second domain is composed of a series of SR repeats (Fig. 1B, 29 repeats are marked by bold underline) that cover much of the carboxyl half of the protein. SR-rich regions have been found in several protein factors that are associated with pre-mRNA splicing (38, 39).

Adjacent to the cyclophilin domain (residue 193) is a stretch of 30 amino acids containing 19 serines and 8 aspartate or glutamate residues (Fig. 1B, dashed underline). This acidic serine region is immediately followed by another stretch of 30 amino acids containing 77% basic residues. Various nuclear localization signal (NLS) binding proteins contain similar domains (40, 41).

Consistent with a nuclear localization of matrin CYP, there are numerous NLS motifs in the amino acid sequence. Three putative NLS motifs are particularly rich in SR repeats (amino acids 342-354, 456-489, and 512-667) and resemble the SR repeat regions of the SuWA and Tra Drosophila splicing proteins that have been demonstrated to target cytoplasmic proteins to the nucleus (42). In addition to the SR-rich regions, matrin CYP contains nine classical NLS motifs as follows: six different bipartite-type NLS (starting at positions 226, 233, 338, 437, 452, 608) and three different SV40 large T antigen-type NLS at positions 226, 243, and 619 (43).

Immunological Analysis of Matrin CYP-- A fusion protein comprising the carboxyl-terminal residues (644-752) of the full-length matrin cyp cDNA (GST/matrin CYP-CT) was expressed, and polyclonal antibodies were raised against this peptide in chickens (see "Experimental Procedures"). This region of matrin CYP was chosen because it did not contain clusters of SR repeats nor significant similarity with other reported proteins.

Rat liver whole cell extracts were subfractionated into cytoplasmic and nuclear fractions and then probed with the purified anti-matrin CYP-CT antibody on immunoblots. The antibody did not stain protein bands in the cytoplasmic fractions but recognized a diffuse band at about 106 kDa in the purified nuclear fraction (Fig. 2, lane 7). Over 90% of the 106-kDa protein was recovered in the nuclear matrix fraction based on a total nuclear protein recovery of 29% in the nuclear matrix and an approximately 3-fold increase in signal from the purified nuclei to the nuclear matrix fractions (Fig. 2, compare lanes 7 and 11). Correspondingly, no anti-matrin CYP-CT signal was detected in the soluble protein fractions obtained from the nuclease digestion, high salt, or detergent extractions used to prepare the nuclear matrices (Fig. 2, lanes 8-10). Similar protein blots stained with anti-lamin A/C and anti-matrin 3 antibodies, both nuclear matrix-associated proteins, resulted in levels of nuclear matrix enrichment and recovery similar to those observed for matrin CYP (data not shown).


View larger version (96K):
[in this window]
[in a new window]
 
Fig. 2.   Immunoblot analysis of subcellular fractions derived from rat liver cells. The lanes were loaded with 5 µg of various rat liver cell fractions as follows: lane 1, whole cell lysate; lane 2, postnuclear supernatant; lane 3, mitochondrial pellet; lane 4, postmitochondrial supernatant; lane 5, microsomal pellet; lane 6, cytosol; lane 7, purified nuclei; lane 8, supernatant from nuclease and high salt wash; lane 9, supernatant from second high salt wash; lane 10, supernatant of detergent extract; lane 11, nuclear matrix. Lanes 12 and 13 are 5 µg of rat liver nuclear matrix proteins probed with anti-matrin CYP-CT (lane 12) or anti-matrin CYP-CT that was preincubated with an equal molar amount of matrin CYP-CT as competitor (lane 13). The signals in lanes 7 and 11 were quantified by densitometry. Molecular mass markers are indicated in kDa.

The specificity of the anti-matrin CYP-CT antibody for the 106-kDa antigen was demonstrated by preincubating the antibody with an equal molar concentration of the matrin CYP-CT fusion protein and then probing rat liver nuclear matrix proteins with this mixture. This resulted in the complete inhibition of binding of the anti-matrin CYP-CT antibody to the 106-kDa antigen (Fig. 2, lane 13), whereas a corresponding mock treatment (Fig. 2, lane 12) had no effect.

The difference observed between the apparent molecular mass of 106 kDa and the predicted molecular mass of 88 kDa based on cDNA sequencing is consistent with the highly charged nature of matrin CYP and previous observations that numerous SR proteins exhibit apparent molecular masses on SDS-polyacrylamide gel electrophoresis that are significantly higher than predicted from amino acid sequences (38, 44-46). Moreover, sequence analysis revealed 46 known phosphorylation motifs in matrin CYP including 19 casein kinase II and 14 protein kinase C sites. Indeed, a phosphatase-mediated shift in the migration of matrin CYP from 106 to 98 kDa (Fig. 3, lane 1) indicates that a significant portion of the higher apparent molecular weight exhibited by matrin CYP is due to a phosphorylated state of this protein in the cell nucleus.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   Phosphatase treatment of rat liver nuclear matrix proteins shift the mobility of matrin CYP. 20 µg of rat liver nuclear matrix protein was incubated with phosphatase inhibitors and potato acid phosphatase (lane 2) or only potato acid phosphatase (lane 1). Lane 3 is a mocked treated sample. Following the treatments, the proteins were separated on a 6% SDS-polyacrylamide gel. Immunoblot analysis was performed with the anti-matrin CYP-CT. Size markers are indicated in kDa.

Matrin CYP Is Localized to Nuclear Speckles during Interphase-- Immunofluoresence analyses using anti-matrin CYP-CT confirmed the immunoblot results indicating that this antibody is highly specific for a nuclear antigen. Double staining immunofluorescence of primary cultured rat parenchymal cells with anti-lamin A/C and anti-matrin CYP-CT was imaged by laser scanning confocal microscopy and revealed that anti-matrin CYP-CT decorated intranuclear structures consisting predominantly of large irregularly shaped foci that do not correspond to the nucleoli (Fig. 4, A-C). Similar structures were stained by anti-matrin CYP-CT using a wide variety of fixation protocols (see "Experimental Procedures") or in other cell lines such as mouse 3T3 fibroblasts or human HeLa cells (data not shown). In addition to the bright foci, a less intense, diffuse staining was detected throughout the nucleoplasm (Fig. 4A). A very low intensity background staining was also consistently observed throughout the cytoplasm.


View larger version (137K):
[in this window]
[in a new window]
 
Fig. 4.   Confocal immunofluorescence microscopy of primary cultures of rat parenchymal cells. A-F, cells were fixed in 3% paraformaldehyde and stained with anti-matrin CYP-CT (A), anti-lamin A/C (B), and merged images (C) or stained with anti-matrin CYP-CT (D), anti-U1-70-kDa (E), and merged images (F). G-I, following extraction of cells for in situ nuclear matrix and stained with anti-matrin CYP-CT (G), anti-lamin A/C (H), and merged images (I).

The specificity of anti-matrin CYP for these various structures was tested by preincubating this antibody with different levels of matrin CYP-CT fusion protein and performing immunofluorescence with these mixtures. By using this competitor peptide approach, the very intense staining of the speckled sites was virtually abolished at an antibody:matrin CYP fusion protein molar ratio of 0.3, whereas the diffuse nucleoplasmic and cytoplasmic staining was not affected (Fig. 5). We conclude that the matrin CYP antibody is at least predominantly decorating matrin CYP at the speckled sites. These findings are consistent with the immunoblot results (Fig. 2) that did not detect matrin CYP antigens in the cytoplasmic fractions from rat liver cells.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 5.   Confocal images of mouse 3T3 fibroblasts stained with anti-matrin CYP-CT following preincubation with a matrin CYP fusion protein. Increasing levels of matrin CYP-CT fusion protein were preincubated with anti-matrin CYP-CT, and the molar ratios of antibody to fusion protein are indicated above a representative cell. The control cells were stained only with the secondary antibody. Cells were fixed with 3% paraformaldehyde.

Rat parenchymal cells in primary culture were extracted for in situ nuclear matrices (see "Experimental Procedures") and then double-stained as above. The results show that, like those observed with immunoblot analysis, the anti-matrin CYP-CT-specific antigens are tightly associated with the nuclear matrix (Fig. 4, G-I). Moreover, this association is maintained in a similar distribution of bright foci and less intense nucleoplasmic staining characteristically observed for fixed cells (Fig. 4, G-I).

Since the predicted amino acid sequence of matrin CYP contains clusters of SR repeats and the nucleoplasmic foci stained by anti-matrin CYP-CT were reminiscent of splicing factor rich nuclear "speckles" observed in other studies (32, 33, 47-49), double labeling immunofluorescence microscopy was performed with anti-splicing factor specific antibodies and anti-matrin CYP-CT. Indeed, antibodies specific for the 70-kDa subunit of the U1 snRNP co-localizes with anti-matrin CYP-CT in rat parenchymal cells (Fig. 4, D-F). Similar results were obtained using other splicing factors (e.g. Y12) or different mammalian cell lines, e.g. mouse 3T3 fibroblasts or human HeLa cells (data not shown).

Matrin CYP Redistributes during Mitosis and Associates with Other Non-snRNP SR Proteins-- Mouse 3T3 cells were synchronized by serum deprivation and examined at times when mitotic figures are maximal (see "Experimental Procedures"). At the onset of mitosis, matrin CYP is remodeled from its characteristic speckle pattern to a more diffuse pattern that is distributed between the condensing chromosomes (Fig. 6A). In late prophase (as the nuclear envelope breaks down) the diffuse staining of matrin CYP extends into the cytoplasm (Fig. 6C). At prometaphase, metaphase, and anaphase (when the chromosomes are fully condensed) the diffuse staining of anti-matrin CYP-CT distributes uniformly throughout the mitotic cytoplasm along with a limited number of small punctate structures (Fig. 6, E, G, and I). The characteristic exclusion of matrin CYP from the chromosomes is maintained throughout mitosis. During telophase, matrin CYP undergoes a significant rearrangement as the diffuse staining becomes less pronounced and many round bright foci are observed scattered throughout the cytoplasm (Fig. 6K).


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 6.   Reorganization of matrin CYP during mitosis in mouse 3T3 fibroblasts. Mouse 3T3 fibroblasts were synchronized by serum deprivation and examined 22 h after serum addition to enrich the population of mitotic cells. These cells were fixed in 3% paraformaldehyde and stained with anti-matrin CYP-CT and DAPI. A and B, early prophase; C and D, late prophase; E and F, prometaphase; G and H, metaphase; I and J, anaphase; K and L, telophase. A, C, E, G, I, and K show anti-matrin CYP-CT staining. B, D, F, H, J, and L show DAPI staining of the same cell.

Similar nuclear redistributions during mitosis have been previously reported for several antibodies specific for non-snRNP SR splicing factors (80). Consistent with these results, we found in late telophase cells a nearly identical localization of anti-matrin CYP-CT and the monoclonal antibody B1C8 (Fig. 7, A and B), which recognizes an SR protein of 160 kDa (33). An antibody specific for a small constellation of non-snRNP, SR proteins, NM-4 (19), also showed a very similar distribution as anti-matrin CYP-CT in late telophase cells (data not shown). In contrast, snRNP proteins, as detected by Y12, localized predominantly to the interior of the nucleus during late telophase and showed no enrichment in the cytoplasmic foci stained by anti-matrin CYP-CT (Fig. 7, D and E). Identical results were obtained using the U1 70-kDa specific antibodies (data not shown).


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 7.   Mouse 3T3 fibroblasts in late telophase show markedly different staining patterns for SR proteins compared with snRNP proteins. A-C shows a cell in late telophase stained with anti-matrin CYP-CT (A), the monoclonal antibody specific for a 180-kDa SR protein termed B1C8 (B), and DAPI (C). D-F shows late telophase stained with anti-matrin CYP-CT (D), the anti-snRNP monoclonal antibody Y12 (E), and DAPI (F).

By using two alternative procedures, we next examined whether matrin CYP fractionates with other SR proteins. Matrin CYP was enriched from 5- to 10-fold on a protein basis in the SR protein fraction of Blencowe et al. (19) compared with the initial HeLa nuclear extract (Fig. 8, lanes 1 and 2). In contrast, matrin CYP was not detected in the classical SR protein preparation of Zahler et al. (50) and was, therefore, highly depleted in this fraction compared with the nuclear extract (Fig. 8, lanes 1 and 3). These results support previous observations (19) that numerous SR-related proteins (including several nuclear matrix proteins) are not present in the final preparations of Zahler et al. (50).


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 8.   Fractionation of matrin CYP with SR proteins. Protein samples were separated on an SDS-polyacrylamide gel and transferred to nitrocellulose membrane using a semi-dry electrotransfer apparatus. Immunoblot analysis was then performed as described under "Experimental Procedures." Anti-matrin CYP-CT recognizes a protein of approximately 106 kDa in a splicing competent HeLa nuclear extract (lane 1, 100 µg of protein). This protein is enriched in a high salt extract from a magnesium-precipitated pellet of this nuclear extract (lane 2, 20 µg of protein) that was previously shown (19) to contain numerous SR-related proteins. Anti-matrin CYP-CT does not recognize an antigen in the fraction enriched for the six soluble SR proteins (lane 3, 100 µg of protein) defined by Zahler et al. (50). Note that anti-matrin CYP-CT shows no cross-reactions with other SR proteins. Protein size markers are indicated in kDa.

Matrin CYP Is a Functional PPIase-- A fusion protein containing the cyclophilin domain of matrin CYP linked to the carboxyl tail of glutathione S-transferase (GST/matrin CYP-NT, see Fig. 1) was expressed in Escherichia coli and purified to over 90% purity from a glutathione bead column (Fig. 9A). GST/matrin CYP-NT was capable of catalyzing the conversion of the cis-proline tetrapeptide substrate, AAPF, to the trans-form in an in vitro assay (Fig. 9B, line a). This activity was well above the spontaneous background observed when no exogenous proteins were added to the assay (Fig. 9B, line g). The isomerase activity is a function of the matrin CYP-NT domain since the GST portion was not capable of acting as a PPIase alone (Fig. 9B, line f). The homologous NK-TR cyclophilin (26) also exhibited PPIase activity, albeit at a slightly lower level than matrin CYP (Fig. 9B, line b). The calculated kcat/Km for GST/matrin CYP-NT is 16-fold lower than those reported for human CYP A, but within the range reported for other cyclophilins using similar tetrapeptide substrates (Table I).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 9.   Peptidylprolyl cis-trans-isomerase activity and inhibition by cyclosporin A in the cyclophilin domain of matrin CYP. A, both GST/matrin CYP-NT and GST/NK-TR cyclophilin were expressed in E. coli and purified to near homogeneity. Cell lysates or purified fusion proteins were run on a 10% SDS-polyacrylamide gel and stained with Coomassie Blue. Lane 1, GST/matrin CYP-NT uninduced; lane 2, GST/matrin CYP-NT induced; lane 3, GST/matrin CYP-NT purified; lane 4, GST/NK-TR uninduced; lane 5, GST/NK-TR induced; lane 6, GST/NK-TR purified. B, GST/matrin CYP-NT, GST/NK-TR, and GST alone were tested for in vitro PPIase activity in a chymotrypsin-coupled assay using the tetrapeptide substrate N-succinyl-AAPF-p-nitroanilide (34). The graph indicates PPIase activity as an increase in absorbance. Line a, 145 nM GST/matrin CYP-NT; line b, 145 nM GST/NK-TR; line c, 36 nM GST/matrin CYP-NT; line d, 100 nM GST/NK-TR and 10 µM CsA; line e, 100 nM GST/matrin CYP-NT and 10 µM CsA; line f, 145 nM GST; line g, no protein added.

                              
View this table:
[in this window]
[in a new window]
 
Table I
PPIase activity assocated with cyclophilin proteins

The PPIase activity of this fusion protein was completely abolished by preincubation with CsA (Fig. 9B, line e) as was its GST/NK-TR counterpart ((Fig. 9B, line d). Matrin CYP had an inhibitory sensitivity to CsA (IC50) of 220 nM that is within the range of IC50 values reported for other cyclophilins (Table I). Obtaining the direct binding constants for CsA and GST/matrin CYP-NT was not feasible for the same reasons as previously discussed for the NK-TR cyclophilin (26).

Functional Nuclear Cyclophilins Associate with the Nuclear Matrix-- Since matrin CYP is quantitatively recovered in the nuclear matrix, we next investigated whether CsA-inhibited PPIase activity is present within endogenous rat liver nuclear matrix proteins. Rat liver nuclear and nuclear matrix proteins were incubated in M urea and 50 mM DTT that resulted in the nearly complete (>90%) solubilization of proteins from these fractions (Fig. 10A, lanes 1 and 3). Most of the protein, including matrin CYP, remained in solution after the urea and DTT were diluted 10,000-fold by dialysis (Fig. 10, A and B, lane 5). The relatively harsh procedure of urea and DTT treatment used to solubilize rat liver nuclear and nuclear matrix proteins had little inhibitory effect on the PPIase activity of similarly treated GST/matrin CYP-NT (>90% recovery of total enzyme activity).


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 10.   Solubilization of total nuclear matrix proteins includes matrin CYP. The majority (>80%) of nuclear matrix proteins, including matrin CYP, remain in the supernatant after solubilization and dialysis. A, rat liver nuclear matrix proteins were solubilized in 9 M urea, 50 mM DTT and dialyzed as described under "Experimental Procedures." Equal volumes were loaded in lanes 1-5 as follows: lane 1, untreated rat liver nuclear matrix (10 µg); lane 2, pellet from urea/DTT-solubilized rat liver nuclear matrix; lane 3, supernatant from urea/DTT-solubilized nuclear matrix; lane 4, pellet from dialyzed and solubilized nuclear matrix; lane 5, supernatant from dialyzed and solubilized nuclear matrix. The gel was stained with Coomassie Blue. B, immunoblot stained with anti-matrin CYP-CT of a gel similar to A. Total nuclear proteins were solubilized similarly to nuclear matrix proteins (data not shown). Size markers are indicated in kDa.

The in vitro PPIase revealed a 2.2-fold higher specific activity in the nuclear matrix proteins compared with the nuclear proteins (Table II). This corresponded to a recovery of 63% of the total nuclear PPIase activity in the nuclear matrix fraction. Moreover, the CsA-sensitive PPIase activity was quantitatively associated with the nuclear matrix fraction (Table II) with a 4.4-fold increase in specific activity compared with the corresponding total nuclear CsA-sensitive activity. In contrast, CsA-resistant activity was not significantly enriched (1.1-fold) on the nuclear matrix compared with the total nuclear activity (Table II).

                              
View this table:
[in this window]
[in a new window]
 
Table II
PPIase activity of the nuclear and nuclear matrix fractions

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The Cyclophilin Domain of Matrin CYP-- Matrin CYP belongs to a highly conserved and large class of proteins termed cyclophilins that function as peptidylprolyl-isomerases (PPIases) to catalyze the conversion of cis-proline to trans-proline in a polypeptide chain. Cyclophilins bind the immunosuppressive drug cyclosporin A that inhibits the associated PPIase activity (51, 52). They are ubiquitous throughout the phylogenetic scale (53) and are located in a wide variety of subcellular compartments (37, 54-63) where they have been proposed to function in protein folding as well as a chaperone for protein targeting and macromolecular assembly (26, 36, 37, 52, 55, 57, 59, 64-69). Initial studies indicate a wide range of functional roles for cyclophilins such as involvement in T-cell activation (70), natural (tumor) killer cell function (71), protein secretion (59, 69), photoreceptor cell function via formation of active forms of rhodopsin 1 and 2 proteins (64, 67), steroid receptor function (68), myeloid cell differentiation (72), tumor cell growth (73), and formation of infectious human immunodeficiency virus-I virions through interactions with the Gag polyprotein (74, 75).

Although matrin CYP is the first cyclophilin demonstrated to be predominantly located within the nucleus, an FK506-binding protein PPIase was previously found in the nucleolus (76), and a parvulin PPIase has been localized to the nuclear speckles (77). Neither of these PPIase activities exhibit sensitivity to CsA. Nestel et al. (78) and Bourquin et al. (79), using the yeast two-hybrid approach, independently identified and sequenced the human homolog of the rat matrin cyp (GenBankTM accession numbers U40763 and X99717, respectively) that is 93% identical in amino acid sequence. Complementing our findings, transient transfection experiments revealed that the overexpressed human matrin CYP protein co-localized at splicing factor-rich nuclear speckles and exhibited a possible nuclear matrix association (79). Matrin CYP also shows significant homology to the cyclophilin containing protein termed NK-TR (GenBankTM accession numbers LO4288 and L04289, Ref. 71). Although originally described as a plasma membrane component, NK-TR may also be a nuclear component involved in myeloid cell maturation (72).

Consistent with the localization of matrin CYP in the cell nucleus and its enrichment in the nuclear matrix, we measured significant levels of PPIase activity associated with isolated rat liver nuclei (Table II). The nearly complete recovery of matrin CYP and its characteristic CsA-sensitive PPIase activity in the nuclear matrix fraction (Table II) indicates that a part (if not all) of the CsA-sensitive PPIase activity in the nucleus and nuclear matrix is contributed by the matrin CYP protein. This suggests an involvement of higher order structure in the important but poorly understood events of protein folding, targeting, and macromolecular assembly at discrete sites of nuclear function (e.g. DNA replication, transcription, and/or RNA splicing).

Possible Functions of Matrin CYP-- Further studies are needed to determine the properties of matrin CYP compared with other SR proteins (39). The SR repeats of matrin CYP, for example, may potentiate specific interactions with other SR proteins (81-83). Enrichment of matrin CYP in a nuclear matrix-associated SR protein fraction (Fig. 8 and Ref. 14) suggests a possible role of matrin CYP in the higher order assembly of SR proteins in the cell nucleus. One property associated with SR proteins is the specific phosphorylation of serine residues present in the serine-arginine dipeptide repeats (39). Misteli and Spector (84) have recently presented a model outlining a central role of protein phosphorylation/dephosphorylation in the spatial and temporal coordination of transcription and pre-mRNA splicing. For example, phosphorylation of SC-35 and other splicing factors by the cyclin-independent mitotic kinase SRPK-1 has been linked to the disruption of nuclear speckles observed at the onset of mitosis (85). Similarly, overexpression of the clk kinase resulted in the redistribution of splicing factors from speckles to a diffuse pattern (86). Clk kinase binds to a number of SR proteins and directs (at least in part) their phosphorylation states (86). Likewise, matrin CYP has recently been identified as a specific clk kinase binding protein via the yeast two-hybrid approach (78). Clk kinase is, therefore, a prime candidate for being involved in matrin CYP phosphorylation and the regulation of matrin CYP function such as its associated PPIase activity.

Evidence suggests that splicing factors undergo a dynamic redistribution after participating in pre-mRNA splicing. This has been demonstrated by the cycling of snRNP and non-snRNP splicing factors to and from nuclear speckles (89) and, more recently, by direct observations in living cells (88). We propose that matrin CYP may act as a molecular chaperone that is involved in the dynamic regulation of the nuclear speckle domains. Through its cyclophilin domain and associated PPIase activity, matrin CYP may hold SR proteins in a state from which they cannot associate with each other. This could prevent undesirable aggregation of splicing factors and would be an efficient means to keep a warehouse of splicing factors ready for the variable expression needs of the cell. In addition, the proline isomerase of matrin CYP may assist proteins in nuclear speckles to properly fold and associate into appropriate macromolecular assemblies.

The dynamic movement of speckle-associated proteins is also closely coupled to RNA polymerase II transcription (88). In this regard, a hyperphosphorylated form of the large subunit of pol II (pol lIo) is associated with pre-mRNA splicing, and a subset of SR proteins may mediate this association through interactions with the highly phosphorylated carboxyl-terminal domain (CTD) of pol IIo (17, 18, 90-92). Recently, a yeast two-hybrid screen has identified the human homolog of matrin CYP as strongly interacting with the CTD of pol II and, thus, a member of this CTD-binding protein family (79, 92). This interaction implicates matrin CYP as a possible regulator in the coordination of transcription and pre-mRNA splicing perhaps through its cyclophilin domain. Indeed, the extraordinarily high proline content of the CTD (2 prolines per heptapeptide repeat or 30% of total amino acids) makes it an obvious target for the matrin CYP proline isomerase.

Interaction of matrin CYP with the CTD of pol II and/or other CTD-binding proteins may, in turn, be regulated by specific phosphorylation events mediated by clk kinase and other protein kinases such as SAPK-1. In this regard, Bourquin et al. (79) demonstrated that human matrin CYP requires the SR repeat motifs (known phosphorylation target sites of the clk kinase, see Ref. 86) to interact with the CTD in vitro. In contrast, all other characterized CTD-binding proteins interact with the CTD at other regions on the proteins (90, 92, 93). The nuclear matrix association of pol IIo (17, 18), matrin CYP (Ref. 79 and this study), and a recently characterized CTD-binding protein termed SCAF8 (94) together imply an important role of nuclear architecture for coupling transcription and RNA splicing in the cell nucleus (87).

    ACKNOWLEDGEMENTS

We thank Dr. Tom Maniatis for supplying the anti-U1-70-kDa and Y12 antibodies; Drs. Nilabh Chaudray and Gunter Blobel for supplying the anti-lamin A/C antibodies; Dr. David Brownstein for the pC-DX cDNA library; Dr. Stephen Anderson for supplying the NK-TR CYP fusion protein construct in pGEX; Dr. Aline Rinfret and Dr. Roydon Price for suggestions concerning the PPIase assay; Drs. David Hakes and Jack Dixon for the pGEX-kt plasmid; Dr. James Sawyer for advice and assistance in preparing the rat parenchymal cells; and Dr. Ping-Chin Cheng for use and maintenance of the confocal microscope. We are particularly grateful to Dr. Phillip Belgrader for purifying the partial length cDNA; Dr. Jagath Samarabandu for computer imaging programming and training; Dr. Ben Blencowe who provided the SR protein preparations, several of the anti-SR protein antibodies, and stimulating discussion; Leigh Leonard who helped prepare the antibodies from chicken eggs; and Jim Stamos for preparing the figures.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant GM 23922 (to R. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF043642.

Dagger To whom correspondence should be addressed: Dept. of Biological Sciences, State University of New York, Buffalo, NY 14260. Tel.: 716-645-2363; Fax: 716-645-2975; E-mail: Berezney{at}acsu.buffalo.edu.

1 The abbreviations used are: RNP, ribonucleoprotein; snRNP, small nuclear ribonucleoprotein; CYP, cyclophilin; CsA, cyclosporin A; CTD, carboxyl-terminal domain of RNA polymerase II large subunit; DTT, dithiothreitol; GST, glutathione S-transferase; NK-TR, natural killer tumor recognition molecule; NLS, nuclear localization signal; PBS, phosphate-buffered saline; PPIase, peptidylprolyl cis-trans-isomerase; pol II, polymerase II; bp, base pair(s); AAPF, Ala-Ala-Pro-Phe; DAPI, 4,6-diamidino-2-phenylindole.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Spector, D. L. (1993) Annu. Rev. Cell Biol. 9, 265-315[CrossRef]
  2. Nakamura, H., Morita, T., and Sato, C. (1986) Exp. Cell Res. 165, 291-297[Medline] [Order article via Infotrieve]
  3. Nakayasu, H., and Berezney, R. (1989) J. Cell Biol. 108, 1-11[Abstract]
  4. Jackson, D. A., Hassan, A. B., Errington, R. J., and Cook, P. R. (1993) EMBO J. 12, 1059-1065[Abstract]
  5. Wansink, D. G., Schul, W., van der Kraan, I., van Steensel, B., van Driel, R., and de Jong, L. (1993) J. Cell Biol. 122, 283-293[Abstract]
  6. Mattaj, I. W. (1994) Nature 372, 727-728[CrossRef][Medline] [Order article via Infotrieve]
  7. Lamond, A. I., and Carmo-Fonseca, M. (1993) Trends Cell Biol. 3, 198-204[CrossRef]
  8. Ascoli, C. A., and Maul, G. G. (1991) J. Cell Biol. 112, 785-795[Abstract]
  9. Dyck, J., Maul, G. G., Miller, W. H., Chen, J. D., Kakizuka, A., and Evans, R. (1994) Cell 76, 333-343[Medline] [Order article via Infotrieve]
  10. Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A., and Dejean, A. (1994) Cell 76, 345-356[Medline] [Order article via Infotrieve]
  11. Berezney, R., and Coffey, D. S. (1974) Biochem. Biophys. Res. Commun 60, 1410-1417[Medline] [Order article via Infotrieve]
  12. Berezney, R., and Coffey, D. S. (1977) J. Cell Biol. 73, 616-637[Abstract/Free Full Text]
  13. Berezney, R., Mortillaro, M. J., Ma, H., Wei, X., and Samarabandu, J. K. (1995) Int. Rev. Cytol. 162, 2-66
  14. Nakayasu, H., and Berezney, R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10312-10316[Abstract]
  15. Dreyfuss, G., Swanson, M. S., and Pinol-Roma, S. (1990) in The Eukaryotic Nucleus: Structure and Function (Strauss, P., and Wilson, S., eds), pp. 503-517, Telford Press, Caldwell, NJ
  16. Feuerstein, N., and Mond, J. J. (1987) J. Biol. Chem. 262, 11389-11397[Abstract/Free Full Text]
  17. Mortillaro, M. J., Blencowe, B. J., Wei, X., Nakayasu, H., Du, L., Warren, S. L., Sharp, P. A., and Berezney, R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8253-8257[Abstract/Free Full Text]
  18. Vincent, M., Lauriault, P., Dubois, M. F., Lavoie, S., Bensaude, O., and Chabot, B. (1996) Nucleic Acids Res. 24, 4649-4652[Abstract/Free Full Text]
  19. Blencowe, B. J., Issner, R., Kim, J., McCaw, P., and Sharp, P. A. (1995) RNA (NY) 1, 852-865[Abstract]
  20. Belgrader, P., Dey, R., and Berezney, R. (1991) J. Biol. Chem. 266, 9893-9899[Abstract/Free Full Text]
  21. Mattern, K. A., Humbel, B. M., Muijsers, A. O., de Jong, L., and van Driel, R. (1996) J. Cell. Biochem. 62, 275-289[CrossRef][Medline] [Order article via Infotrieve]
  22. Okayama, H., Kawaichi, M., Brownstein, M., Lee, F., Yokota, T., and Arai, K. (1987) Methods Enzymol. 154, 3-28[Medline] [Order article via Infotrieve]
  23. Sanger, F., Nicklen, S., and Colson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5453-5467[Abstract]
  24. Hakes, D. J., and Dixon, J. E. (1992) Anal. Biochem. 202, 293-298[Medline] [Order article via Infotrieve]
  25. Smith, D. B., and Johnson, K. S. (1988) Gene (Amst.) 67, 31-40[CrossRef][Medline] [Order article via Infotrieve]
  26. Rinfret, A., Collins, C., Menard, R., and Anderson, S. K. (1994) Biochemistry 33, 1668-1673[Medline] [Order article via Infotrieve]
  27. Song, C. S., Yu, J. H., Bai, D. H., Hester, P. Y., and Kim, K. H. (1985) J. Immunol. 135, 3354-3359[Abstract/Free Full Text]
  28. Basler, J., Hastie, N. D., Pietras, D., Matsui, S., Sandburg, A. A., and Berezney, R. (1981) Biochemistry 20, 6921-6929[Medline] [Order article via Infotrieve]
  29. Papavassiliou, A. G., and Bohmann, D. (1992) Methods Mol. Cell Biol. 3, 149-152
  30. Seglen, P. O. (1976) Methods Cell Biol. 13, 29-83[Medline] [Order article via Infotrieve]
  31. Reuter, R., Appel, B., Rinke, J., and Luhrmann, R. (1985) Exp. Cell Res. 159, 63-79[Medline] [Order article via Infotrieve]
  32. Nyman, U., Hallman, H., Hadlaczky, G., Pettersson, I., Sharp, G., and Ringertz, N. R. (1986) J. Cell Biol. 102, 137-144[Abstract]
  33. Blencowe, B. J., Nickerson, J. A., Issner, R., Penman, S., and Sharp, P. A. (1994) J. Cell Biol. 127, 593-607[Abstract]
  34. Kofron, J. L., Kuzmic, P., Kinshore, V., Colon-Bonilla, E., and Rich, D. H. (1991) Biochemistry 30, 6127-6134[Medline] [Order article via Infotrieve]
  35. Kozak, M. (1991) J. Biol. Chem. 266, 19867-19870[Free Full Text]
  36. Fischer, G., Wittman-Liebold, B., Lang, K., Kiefhaber, T., and Schmid, F. X. (1989) Nature 337, 476-478[CrossRef][Medline] [Order article via Infotrieve]
  37. Freskgard, P. O., Bergenham, N., Jonsson, B. H., Svensson, M., and Carlsson, U. (1992) Science 258, 466-468[Medline] [Order article via Infotrieve]
  38. Zahler, A. M., Neugebauer, K. M., Stolk, J. A., and Roth, M. B. (1993) Mol. Cell. Biol. 13, 4023-4028[Abstract]
  39. Fu, X. D. (1995) RNA (NY) 1, 663-680[Medline] [Order article via Infotrieve]
  40. Meir, U. T., and Blobel, G. (1992) Cell 70, 127-138[Medline] [Order article via Infotrieve]
  41. Goday, A., Jensen, A. A., Culianez-Macia, F. A., Mar Alba, M., Figueras, M., Serratosa, J., and Torrent, M. P. M. (1994) Plant Cell 6, 351-360[Abstract/Free Full Text]
  42. Li, H., and Bingham, P. M. (1991) Cell 67, 335-342[Medline] [Order article via Infotrieve]
  43. Dingwall, C., and Laskey, R. A. (1991) Trends Biochem. Sci. 16, 478-481[CrossRef][Medline] [Order article via Infotrieve]
  44. Query, C. C., Bentley, R. C., and Keene, J. D. (1989) Cell 57, 89-101[Medline] [Order article via Infotrieve]
  45. Krainer, A. R., Mayeda, A., Kozak, D., and Binns, G. (1991) Cell 66, 383-394[Medline] [Order article via Infotrieve]
  46. Roth, M. B., Zahler, A. M., and Stolk, J. A. (1991) J. Cell Biol. 115, 587-596[Abstract]
  47. Spector, D. L., Schrier, W. H., and Busch, H. (1983) Biol. Cell 49, 1-10[Medline] [Order article via Infotrieve]
  48. Spector, D. L. (1984) Biol. Cell 51, 109-112[Medline] [Order article via Infotrieve]
  49. Verheijen, R., Kuijpers, H., Vooijs, P., van Venrooij, W., and Ramaekers, F. (1986) J. Cell Sci. 80, 103-122[Abstract]
  50. Zahler, A. M., Lane, W. S., Stolk, J. A., and Roth, M. B. (1992) Genes Dev. 6, 837-847[Abstract]
  51. Walsh, C. T., Zydowsky, L. D., and McKeon, F. D. (1992) J. Biol. Chem. 267, 13115-13118[Abstract/Free Full Text]
  52. Galat, A., and Metcalfe, S. M. (1995) Prog. Biophys. Mol. Biol. 63, 67-118[CrossRef][Medline] [Order article via Infotrieve]
  53. Fruman, D. A., Burakoff, S. J., and Bierer, B. E. (1994) FASEB 8, 391-400[Abstract/Free Full Text]
  54. Kieffer, L. J., Seng, T. W., Li, W., Osterman, D. G., Handschumacher, R. E., and Bayney, R. M. (1993) J. Biol. Chem. 268, 12303-12310[Abstract/Free Full Text]
  55. Price, E. R., Zydowsky, L. D., Jin, M., Baker, C. H., McKeon, F. D., and Walsh, C. T. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1903-1907[Abstract]
  56. Spik, G., Haendler, B., Delmas, O., Mariller, C., Chamoux, M., Maes, P., Tartar, A., Montreuil, J., Stedman, K., Kocher, H. P., Keller, R., Hiestand, P. C., and Movva, N. R. (1991) J. Biol. Chem. 266, 10735-10738[Abstract/Free Full Text]
  57. Caroni, P., Rothenfluh, A., McGlynn, E., and Schneider, C. (1991) J. Biol. Chem. 266, 10739-10742[Abstract/Free Full Text]
  58. Friedman, J., and Weissman, I. (1991) Cell 66, 799-806[Medline] [Order article via Infotrieve]
  59. Hasel, K. W., Glass, J. R., Godbout, M., and Sutcliffe, J. G. (1991) Mol. Cell. Biol. 11, 3484-3491[Medline] [Order article via Infotrieve]
  60. Bergsma, D. J., Eder, C., Gross, M., Kersten, H., Sylvester, D., Appelbaum, E., Cusimano, D., Livi, G. P., McLaughlin, M. M., Kasyan, K., Porter, T. G., Silverman, C., Dunnington, D., Hand, A., Prichett, W. P., Bossard, M. J., Brandt, M., and Levy, M. A. (1991) J. Biol. Chem. 266, 23204-23214[Abstract/Free Full Text]
  61. Lippuner, V., Chou, I. T., Scott, S. V., Ettinger, W. F., Theg, S. M., and Gasser, C. S. (1994) J. Biol. Chem. 269, 7863-7868[Abstract/Free Full Text]
  62. Wu, J., Matunis, M. J., Kraemer, D., Blobel, G., and Coutavas, E. (1995) J. Biol. Chem. 270, 14209-14213[Abstract/Free Full Text]
  63. Yokoyama, N., Hayashi, N., Seki, T., Pante, N., Ohba, T., Nishii, K., Kuma, K., Hayashida, T., Miyata, T., and Aebi, U. (1995) Nature 376, 184-188[CrossRef][Medline] [Order article via Infotrieve]
  64. Stamnes, M. A., Shieh, B., Chuman, L., Harris, G. L., and Zuker, C. S. (1991) Cell 65, 219-227[Medline] [Order article via Infotrieve]
  65. Steinmann, B., Bruckner, P., and Superti-Furga, A. (1991) J. Biol. Chem. 266, 1299-1303[Abstract/Free Full Text]
  66. Heitman, J., Movva, N. R., and Hall, M. N. (1992) New Biol. 4, 448-460[Medline] [Order article via Infotrieve]
  67. Ferreira, P. O., Nakayama, T. A., Pak, W. L., and Travis, G. H. (1996) Nature 383, 637-640[CrossRef][Medline] [Order article via Infotrieve]
  68. Freeman, B. C., Toft, D. O., and Morimoto, R. I. (1996) Science 274, 1718-1720[Abstract/Free Full Text]
  69. Price, E. R., Jin, M., Lim, D., Pati, S., Walsh, C. T., and McKeon, F. D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3931-3935[Abstract]
  70. Handschumacher, R. E., Harding, M. W., Rice, J., Drugge, R. J., and Speicher, D. W. (1984) Science 226, 544-547[Medline] [Order article via Infotrieve]
  71. Anderson, S. K., Gallinger, S., Rooder, J., Frey, J., Young, H. A., and Ortaldo, J. R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 542-546[Abstract]
  72. Giardina, S. L., Coffman, J. D., Young, H. A., Potter, S. J., Frey, J. L., Ortaldo, J. R., and Anderson, S. K. (1996) Blood 87, 2269-2274[Abstract/Free Full Text]
  73. Nair, A. P., Hahn, S., Banholzer, R., Hirsch, H. H., and Moroni, C. (1994) Nature 369, 239-242[CrossRef][Medline] [Order article via Infotrieve]
  74. Franke, E. T., Yuan, H. E. H., and Kuban, J. (1994) Nature 372, 359-362[CrossRef][Medline] [Order article via Infotrieve]
  75. Thali, M., Bukovsky, A., Kondo, E., Rosenwirth, B., Walsh, C. T., Sodroski, J., and Gottlinger, H. G. (1994) Nature 372, 363-365[CrossRef][Medline] [Order article via Infotrieve]
  76. Shan, X., Xue, Z., and Melese, T. (1994) J. Cell Biol. 126, 853-862[Abstract]
  77. Lu, K. P., Hanes, S. D., and Hunter, T. (1996) Nature 380, 544-547[CrossRef][Medline] [Order article via Infotrieve]
  78. Nestel, F. P., Colwill, K., Pawson, T., and Anderson, S. K. (1996) Gene (Amst.) 180, 151-155[CrossRef][Medline] [Order article via Infotrieve]
  79. Bourquin, J. P., Stagljar, I., Meier, P., Moosmann, P., Silke, J., Baechi, T., Georgiev, O., and Schaffner, W. (1997) Nucleic Acids Res. 25, 2055-2061[Abstract/Free Full Text]
  80. Ferreira, J. A., Carmo-Fonseca, M., and Lamond, A. I. (1994) J. Cell Biol. 126, 11-23[Abstract]
  81. Wu, J. Y., and Maniatis, T. (1993) Cell 75, 1061-1070[Medline] [Order article via Infotrieve]
  82. Kohtz, J. D., Jamison, S. F., Will, C. L., Zuo, P., Luhrmann, R., Barcia-Blanco, M. A., and Manley, J. L. (1994) Nature 368, 119-124[CrossRef][Medline] [Order article via Infotrieve]
  83. Amrein, H., Hedley, M. L., and Maniatis, T. (1994) Cell 78, 735-746
  84. Misteli, T., and Spector, D. L. (1997) Trends Cell Biol. 7, 135-138[CrossRef]
  85. Gui, J.-F., Lane, W. S., and Fu, X.-D. (1994) Nature 369, 678-682[CrossRef][Medline] [Order article via Infotrieve]
  86. Colwill, K., Pawson, T., Andrews, B., Prasad, J., Manley, J. L., Bell, J. C., and Duncan, P. I. (1996) EMBO J. 15, 265-275[Abstract]
  87. Xing, Y., Johnson, C. V., Moen, P. T., McNeil, J. A., and Lawrence, J. B. (1995) J. Cell Biol. 131, 1635-1647[Abstract]
  88. Misteli, T., Caceres, J. F., and Spector, D. L. (1997) Nature 387, 523-526[CrossRef][Medline] [Order article via Infotrieve]
  89. Jimenez-Garcia, L. F., and Spector, D. L. (1993) Cell 73, 47-59[Medline] [Order article via Infotrieve]
  90. Yuryev, A., Patturajan, M., Litingtung, Y., Joshi, R. V., Gentile, C., Gebara, M., and Corden, J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6975-6980[Abstract/Free Full Text]
  91. Kim, E., Du, L., Bregman, D. B., and Warren, S. L. (1997) J. Cell Biol. 136, 19-28[Abstract/Free Full Text]
  92. Corden, J. L., and Patturajan, M. (1997) Trends Biochem. Sci. 22, 413-416[CrossRef][Medline] [Order article via Infotrieve]
  93. Tanner, S., Stagljar, I., Georgiev, O., Schaffner, W., and Bourquin, J. P. (1997) J. Biol. Chem. 378, 565-571
  94. Patturajan, M., Wei, X., Berezney, R., and Corden, J. L. (1998) Mol. Cell. Biol., in press


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.